|
AGREE II domain 1: scope and purpose
|
Q13 Are the purpose and target users of the guideline stated?
|
Q1. The overall objectives of the guideline are specifically described
|
| |
Q2. The health questions covered by the guideline are specifically described
|
| |
Q3. The population to whom the guideline is meant to apply is specifically described
|
|
AGREE II domain 2: stakeholder involvement
| |
Q6. The target users are clearly defined
|
|
Q11. Are the developers clearly stated?
|
Q4. The guideline development group includes individuals from all relevant professional groups
|
|
Q12. Does the qualifications and expertise of the guideline developers link with the purpose of the guideline and its end users?
|
Q5. The views and preferences of the target population have been sought
|
|
AGREE II domain 3: rigour of development
|
Q7. Does the guideline provide an outline of the strategy used to find underlying evidence?
|
Q7. Systematic methods were used to search for the evidence
|
|
Q8. Does the guideline use a hierarchy to rank the quality of the underlying evidence?
|
Q8. The criteria for selecting the evidence are clearly described
|
|
Q9. Does the guideline appraise the quality of the evidence which underpins its recommendations?
|
Q9. The strengths and limitations of the body of evidence are clearly described
|
|
Q10. Does the guideline link the hierarchy and quality of underlying evidence to each recommendation?
|
Q10. The methods for formulating the recommendations are clearly described
|
| |
Q11. The health benefits, side effects and risks have been considered in formulating the recommendations
|
| |
Q12. There is an explicit link between the recommendations and the supporting evidence
|
| |
Q13. The guideline has been eternally reviewed by experts prior to its publication
|
| |
Q14. A procedure for updating the guideline is provided
|
|
iCAHE instrument domain: currency
|
Q4. Is there a date of completion available?
| |
|
Q5. Does the guideline provide an anticipated review date?
| |
|
Q6. Does the guideline provide dates for when literature was included?
| |
|
AGREE II domain 4: clarity of presentation
|
Q14. Is the guideline readable and easy to navigate?
|
Q15. The recommendations are specific and unambiguous
|
| |
Q16. The different options for management of the condition or health issues are clearly presented
|
| |
Q17. Key recommendations are easily identifiable
|
|
AGREE II domain 5: applicability
| |
Q18. The guideline describes facilitators and barriers to its application
|
| |
Q19. The guideline provides advice and/or tools on how the recommendations can be put into practice
|
| |
Q20. The potential resources implications of applying the recommendations have been considered
|
| |
Q21. The guideline presents monitoring and/or auditing criteria
|
|
AGREE II domain 6: editorial independence
| |
Q22. The views of the funding body have not influenced the content of the guideline
|
| |
Q23. Competing interests of guideline development group members have been recorded and addressed
|
|
iCAHE instrument domain: availability
|
Q1. Is the guideline readily available in full text?
| |
|
Q2. Does the guideline provide a complete reference list?
| |
|
iCAHE instrument domain: summary
|
Q3. Does the guideline provide a summary of its recommendations?
| |
